[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559490":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":28,"interventions":40,"overallOfficials":46,"centralContacts":51,"locations":57,"responsibleParty":75,"collaborators":17,"id":78,"slug":17,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":17,"eligibilityCriteria":82,"healthyVolunteers":79,"sex":83,"minAge":84,"maxAge":17,"enrollmentInfo":85,"targetDuration":17,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":17,"overallStatus":60,"whyStopped":17,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Universidad Autonoma de Nuevo Leon","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Treatment response","porcentage of hair growth determined by SALT score","5 months",[14],{"measure":15,"description":16,"timeFrame":12},"Side effects","Side effects associated to the treatment",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"TRIPLE",[25,26,27],"PARTICIPANT","CARE_PROVIDER","OUTCOMES_ASSESSOR",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"intralesional Triamcinolone","ACTIVE_COMPARATOR","Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg\u002FmL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL",[34],"Drug: Candida Albicans Antigen Injection",{"label":36,"type":37,"description":38,"interventionNames":39},"Candida albicans antigen","EXPERIMENTAL","Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches",[34],[41],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":17},"DRUG","Candida Albicans Antigen Injection","subcutaneous administration of Candida albicans antigen",[36,30],[47],{"name":48,"affiliation":49,"role":50},"Fania Muñoz Garza, PhD","Hospital Universitario \"Dr. José E. González\"","PRINCIPAL_INVESTIGATOR",[52],{"name":53,"role":54,"phone":55,"phoneExt":17,"email":56},"Erika Alba-Rojas, MD","CONTACT","+528183891111","eri9ar@yahoo.com",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Hospital Universitario \"Dr. José Eleuterio González\"","RECRUITING","Monterrey","Nuevo León","64460","Mexico","MX",{"type":67,"coordinates":68},"Point",[69,70],-100.31721,25.68435,{"lat":70,"lon":69},[73],{"name":74,"role":54,"phone":55,"phoneExt":17,"email":56},"Erika Alba Rojas, MD",{"type":50,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Erika Lizbeth Alba Rojas","Erika Alba Rojas","100559490",false,"NCT06564805","Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata","Inclusion Criteria:\n\n* Diagnosis of alopecia areata\n* SALT score of less than 50% extension\n* Has not received any topical or systemic treatment in the last month\n* Signed informed consent\n\nExclusion Criteria:\n\n* Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features\n* Pregnancy or breast-feeding\n* Patients in medications that could cause hair loss as side-effects","ALL","6 Years",{"count":86,"type":87},30,"ESTIMATED","INTERVENTIONAL",[90],"NA","The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.",[93],"Alopecia Areata","2024-08-19",{"date":96,"type":97},"2024-08-21","ACTUAL",{"date":99,"type":97},"2024-08-20",{"date":101,"type":87},"2025-12-31",{"name":5,"class":6},1]